Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | PGR | P06401 | 9/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2391778 | 0.94 | CYP3A4 (0.50) | CYP3A4CYP2C9CYP2C19KCNH2PGR | |
| SCHEMBL2390687 | 0.90 | CYP3A4 (0.45) | CYP3A4CYP2C9CYP2C19MAPK1 | |
| SCHEMBL2387387 | 0.89 | CYP3A4 (0.43) | CYP3A4CYP2C9CYP2C19KCNH2MEN1 | |
| SCHEMBL2390454 | 0.86 | CYP3A4 (0.47) | CYP3A4CYP2C9CYP2C19KCNH2PGR | |
| SCHEMBL2392390 | 0.84 | CYP3A4 (0.54) | CYP3A4CYP2C9CYP2C19KCNH2MAPK1 | |
| SCHEMBL2390579 | 0.84 | CYP3A4 (0.49) | CYP3A4CYP2C9CYP2C19KCNH2MEN1 | |
| SCHEMBL2390253 | 0.84 | CYP3A4 (0.49) | CYP3A4CYP2C9CYP2C19KCNH2MEN1 | |
| SCHEMBL2392658 | 0.83 | CYP3A4 (0.49) | CYP3A4CYP2C9CYP2C19KCNH2MEN1 | |
| SCHEMBL2395098 | 0.83 | CYP3A4 (0.43) | CYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL2390850 | 0.83 | CYP3A4 (0.41) | CYP3A4CYP2C9CYP2C19MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155692-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-06-17 | — | — | EP | claimed |
| US-8026362-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-09-27 | — | — | US | claimed |
| EP-2155692-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-02-24 | — | — | EP | claimed |
| US-20090076045-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2009-03-19 | — | — | US | claimed |
| WO-2008145562-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-04 | — | — | WO | claimed |
| EP-2155692-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-06-17 | — | — | EP | disclosed |
| US-8026362-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-09-27 | — | — | US | disclosed |
| EP-2155692-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-02-24 | — | — | EP | disclosed |
| US-20090076045-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2009-03-19 | — | — | US | disclosed |
| WO-2008145562-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076045-A1 | Non-nucleoside reverse transcriptase inhibitors | HPRT1, XDH, REV1 | CYP3A4 960/4885CYP2C9 1232/4885CYP2C19 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.